文献速递临床试验与 GCP基础与转化研究

黑猩猩腺病毒3型载体马尔堡病毒(cAd3-Marburg)疫苗在健康成人中的安全性、耐受性和免疫原性:美国首次人体、1期、开放标签、剂量递增试验

Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial.
PubMed 文献 · Lancet · 2023-01-01

该研究为在美国开展的首个人体1期开放标签剂量递增试验,40名健康成人分别接种单剂1×10^10或1×10^11 pu的cAd3-Marburg疫苗。疫苗安全耐受,未发生相关严重不良事件,最常见为注射部位疼痛和压痛。接种后4周95%受试者产生糖蛋白特异性抗体,48周时70%受试者抗体仍维持。

要点

  • cAd3-Marburg疫苗在健康成人中安全耐受,未发生疫苗相关严重不良事件。
  • 单剂接种后4周,95%(38/40)受试者产生糖蛋白特异性抗体。
  • 接种后48周,70%受试者糖蛋白特异性抗体仍维持。

核心结论

  • 该首次人体试验表明cAd3-Marburg疫苗安全且有免疫原性,安全性特征与既往测试的cAd3载体丝状病毒疫苗相似。
  • 单剂接种后4周95%的受试者产生糖蛋白特异性抗体应答,48周时70%的受试者仍维持该应答。

研究设计与样本

  • 在美国沃尔特·里德陆军研究所临床试验中心开展的首次人体、1期、开放标签、剂量递增试验。
  • 40名18-50岁健康成人分配接受单次肌内注射cAd3-Marburg疫苗,剂量为1×10^10 pu(n=20)或1×10^11 pu(n=20)。
  • 主要安全性终点为接种后7天内的反应原性和28天内的所有不良事件。
  • 次要免疫原性终点为接种后4周针对马尔堡病毒糖蛋白插入片段的结合抗体应答和T细胞应答,以及针对cAd3载体的中和抗体应答。

主要发现

  • 所有入组受试者均接种了cAd3-Marburg疫苗,37名(93%)完成随访,2名(5%)搬离该地区,1名(3%)失访。
  • 未发生与疫苗接种相关的严重不良事件。
  • 轻度至中度反应原性常见,包括注射部位疼痛和压痛(27/40,68%)、不适(18/40,45%)、头痛(17/40,43%)和肌痛(14/40,35%)。
  • 接种后4周,38/40(95%)受试者诱导出糖蛋白特异性抗体,几何平均滴度为1×10^10 pu组421(95% CI 209-846),1×10^11 pu组545(95% CI 276-1078)。
  • 与基线滴度相比,48周时抗体仍显著升高:1×10^10 pu组39(95% CI 13-119),1×10^11 pu组27(95% CI 9-156),均p<0.0001。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: WHO has identified Marburg virus as an emerging virus requiring urgent vaccine research and development, particularly due to its recent emergence in Ghana. We report results from a first-in-human clinical trial evaluating a replication-deficient recombinant chimpanzee adenovirus type 3 (cAd3)-vectored vaccine encoding a wild-type Marburg virus Angola glycoprotein (cAd3-Marburg) in healthy adults. METHODS: We did a first-in-human, phase 1, open-label, dose-escalation trial of the cAd3-Marburg vaccine at the Walter Reed Army Institute of Research Clinical Trials Center in the USA. Healthy adults aged 18-50 years were assigned to receive a single intramuscular dose of cAd3-Marburg vaccine at either 1 × 1010 or 1 × 1011 particle units (pu). Primary safety endpoints included reactogenicity assessed for the first 7 days and all adverse events assessed for 28 days after vaccination. Secondary immunogenicity endpoints were assessment of binding antibody responses and T-cell responses against the Marburg virus glycoprotein insert, and assessment of neutralising antibody responses against the cAd3 vector 4 weeks after vaccination. This study is registered with ClinicalTrials.gov, NCT03475056. FINDINGS: Between Oct 9, 2018, and Jan 31, 2019, 40 healthy adults were enrolled and assigned to receive a single intramuscular dose of cAd3-Marburg vaccine at either 1 × 1010 pu (n=20) or 1 × 1011 pu (n=20). The cAd3-Marburg vaccine was safe, well tolerated, and immunogenic. All enrolled participants received cAd3-Marburg vaccine, with 37 (93%) participants completing follow-up visits; two (5%) participants moved from the area and one (3%) was lost to follow-up. No serious adverse events related to vaccination occurred. Mild to moderate reactogenicity was observed after vaccination, with symptoms of injection site pain and tenderness (27 [68%] of 40 participants), malaise (18 [45%] of 40 participants), headache (17 [43%] of 40 participants), and myalgia (14 [35%] of 40 participants) most commonly reported. Glycoprotein-specific antibodies were induced in 38 (95%) of 40 participants 4 weeks after vaccination, with geometric mean titres of 421 [95% CI 209-846] in the 1 × 1010 pu group and 545 [276-1078] in the 1 × 1011 pu group, and remained significantly elevated at 48 weeks compared with baseline titres (39 [95% CI 13-119] in the 1 ×1010 pu group and 27 [95-156] in the 1 ×1011 pu group; both p<0·0001). T-cell responses to the glycoprotein insert and neutralising responses against the cAd3 vector were also increased at 4 weeks after vaccination. INTERPRETATION: This first-in-human trial of this cAd3-Marburg vaccine showed the agent is safe and immunogenic, with a safety profile similar to previously tested cAd3-vectored filovirus vaccines. 95% of participants produced a glycoprotein-specific antibody response at 4 weeks after a single vaccination, which remained in 70% of participants at 48 weeks. These findings represent a crucial step in the development of a vaccine for emergency deployment against a re-emerging pathogen that has recently expanded its reach to new regions. FUNDING: National Institutes of Health.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Hamer MJ, Houser KV, Hofstetter AR, et al. Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial. Lancet. 2023. PMID: 36709074. doi:10.1016/S0140-6736(22)02400-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。